Reneo Pharmaceuticals trading is set to resume at 9:50 am ET, with quoting scheduled to resume at 9:45 am ET, according to Nasdaq. Trading in Reneo shares had been halted ahead of the company announcing that its pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies, or PMM, did not meet its primary efficacy or secondary efficacy endpoint.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RPHM:
- Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Block upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- Reneo Pharmaceuticals initiated with an Outperform at William Blair
- Reneo Pharmaceuticals files $300M mixed securities shelf
- Reneo Pharmaceuticals reports Q3 EPS (57c), consensus (57c)
